Personalised treatment planner
Not every treatment works for every child. Answer a few questions to see which options fit, when combining treatments makes sense, and how to tell whether the plan is working. Nothing you enter leaves your device.
What the research says about combining treatments
Combining treatments is common, but the trials give a mixed picture. A summary of the studies in Contact Lens Spectrum (2024):
| Combination | Study | Finding |
|---|---|---|
| Atropine 0.01% + ortho-k | Kinoshita 2020 (2-year RCT) | Slowed eye growth compared with ortho-k alone, but only up to about 12 months. |
| Atropine 0.01% + ortho-k | Tan 2023 (2-year RCT) | Better than either alone only for the first 6 months. |
| Atropine 0.01% + ortho-k | Zhao 2021 | More effective than ortho-k alone in younger children and in eyes with shorter axial length. |
| Atropine 0.01% + ortho-k | Chen 2022 | In children whose eyes kept growing on ortho-k, adding atropine gave no extra benefit at 2 years. |
| Atropine + defocus spectacle lenses (DIMS) | Huang 2022 (Asian children, 1 year) | Improved both eye growth and glasses power compared with lenses alone. |
| Atropine + defocus spectacle lenses (DIMS) | Nucci 2023 (European children, 1 year) | Improved glasses power but not eye growth. |
| Atropine 0.01% + soft multifocal contact lenses | Jones 2022; Erdinest 2022 | No added benefit from adding atropine. |
| Red light + other treatments | None | No trials of combinations have been reported. |
This planner supports a conversation; it does not prescribe. Treatment depends on a full eye examination, the child's retina and cornea, and what is available in your country. Always follow your own eye doctor's advice.